Country Guide: Filing a Patent in India

India is the world's most populous country, the fifth-largest economy, and home to a patent system that is simultaneously one of the most demanding and most misunderstood of any major jurisdiction. For inventors in pharmaceuticals, biotechnology, software, clean energy, agricultural technology, and advanced manufacturing — sectors where India is either a major market, a major manufacturer, or both — Indian patent protection raises strategic questions that cannot be answered by simply applying US or European frameworks.

India's Patent Act contains provisions that are unique in the world and that have been tested in high-stakes litigation by some of the largest pharmaceutical companies on earth. Understanding these provisions — particularly Section 3(d), which governs incremental pharmaceutical innovations — is not just legally important. It is commercially essential for any inventor whose technology touches human health.

The Hard Truth About Indian Patents

India's patent system is demanding in ways that surprise many foreign inventors, and permissive in ways that surprise others.

More demanding than expected: India's patent examination backlog has historically been severe — first examinations sometimes taking 4–6 years. While the Indian Patent Office (IPO) has made significant progress in reducing backlogs since 2016, examination timelines remain longer than the US, Europe, Japan, or Korea. Pre-grant opposition proceedings — in which any person can challenge a pending application before it is granted — are available in India and are actively used by generic pharmaceutical manufacturers and civil society organisations against pharmaceutical patents. Post-grant opposition is also available. The cumulative effect is that challenging a patent in India is significantly more accessible than in most other major jurisdictions.

More permissive than expected: India's patent examination fees are among the lowest of any major jurisdiction. The 12-month grace period for inventor disclosures is one of the most generous available. And for technology sectors outside the contested pharmaceutical space, Indian patent prosecution is often straightforward and produces commercially useful patents without the adversarial challenges that dominate pharmaceutical patent litigation.

The Section 3(d) reality: India's Section 3(d) of the Patents Act 1970 (as amended) prohibits the grant of patents for new forms of known substances — including new salts, esters, polymorphs, metabolites, and other derivatives — unless they demonstrate "significantly enhanced efficacy" compared to the known substance. This provision, introduced in the 2005 amendments, was directly designed to prevent "evergreening" — the practice of obtaining successive patents on minor modifications of known pharmaceutical compounds to extend effective market exclusivity. It was upheld in the landmark Supreme Court decision in Novartis AG v. Union of India (2013), which rejected Novartis's patent application for the beta-crystalline form of imatinib mesylate (Gleevec/Glivec). The implications for pharmaceutical inventors are profound: India is the world's largest supplier of generic medicines, and its patent framework is deliberately structured to maintain access to those medicines.

India's Patent System: Overview

The Indian Patent Office (IPO)

The IPO (also called the Controller General of Patents, Designs and Trade Marks — CGPDTM) administers patents through four patent offices in Mumbai (head office), Chennai, Delhi, and Kolkata. Applications are allocated to patent offices based on the applicant's place of business or residence.

Filing volumes: Approximately 65,000–70,000 patent applications are filed per year, of which foreign applicants account for approximately 50%. Examination backlogs have reduced from peak levels of 7–8 years to approximately 3–5 years for first examination, with ongoing IPO efforts to further reduce timelines.

Types of Protection

Patent:

• Term: 20 years from filing date
• Examination: Full substantive examination
• Application types: Ordinary application, PCT national phase application, application with convention priority (Paris Convention)

No utility model system: India does not have a utility model or petty patent. There is no fast-track registration mechanism comparable to China's utility model or Germany's Gebrauchsmuster.

Design registration: Under the Designs Act 2000. Term: 10 years (renewable once for 5 years, total 15 years). Examination conducted separately.

India's Unique Patentability Provisions

Section 3 Exclusions

Section 3 of the Indian Patents Act 1970 contains a list of subject matter that is not patentable in India. Several provisions are distinctive globally:

Section 3(d) — Incremental pharmaceutical innovations: New forms of known substances are not patentable unless they exhibit "significantly enhanced efficacy." This covers:

• New salts, esters, ethers, polymorphs, metabolites, pure forms, particle sizes, isomers, mixtures of isomers, complexes, combinations, and other derivatives of known substances

The only exception is if the applicant can demonstrate enhanced efficacy — and the IPO's interpretation of "efficacy" in the pharmaceutical context means therapeutic efficacy (clinical benefit), not merely improved bioavailability, solubility, or other physicochemical properties.

Practical implication for pharmaceutical inventors: If your invention involves a new form or derivative of a known pharmaceutical compound, budget for a genuine efficacy analysis and prepare clinical or preclinical data demonstrating enhanced therapeutic effect. Arguments based solely on improved stability, solubility, or processability are not sufficient to satisfy Section 3(d).

Section 3(k) — Software and business methods: "A mathematical or business method or a computer programme per se or algorithms" are not patentable. The phrase "per se" is important — the IPO has adopted guidelines (most recently updated in 2017) that allow software patents where the claimed invention demonstrates a "technical contribution" and is not a mere computer program. A software-implemented invention that controls a physical process, improves computer hardware performance, or produces a technical output beyond the normal execution of a program may be patentable.

Section 3(e) — Mixtures of known substances: "A substance obtained by a mere admixture resulting only in the aggregation of the properties of the components thereof" is not patentable. This is the chemistry equivalent of Section 3(d) — a mixture that achieves only the predictable sum of its components' properties does not involve an inventive step in Indian law.

Section 3(i) — Medical methods: Methods of diagnosis, treatment, or surgery of humans and animals are not patentable. Medical devices, pharmaceutical compositions, and diagnostic reagents are patentable — the exclusion applies to method claims, not product claims.

Section 3(j) — Plant and animal varieties: Plant and animal varieties, essentially biological processes for producing plants and animals, and biological seeds are not patentable. Microorganisms are patentable (a distinction from some other jurisdictions).

Pre-Grant and Post-Grant Opposition

India's opposition mechanisms are among the most accessible of any major patent jurisdiction — a deliberate policy choice rooted in the public health rationale for India's patent law.

Pre-grant opposition (Section 25(1)): Any person may file a pre-grant opposition against a pending patent application after it is published. Grounds include lack of novelty, obviousness, non-patentable subject matter (including Section 3 grounds), insufficient disclosure, and others. Pre-grant oppositions are decided by the Controller of Patents (the IPO examiner) before grant. They are actively used against pharmaceutical patent applications by generic manufacturers, patient advocacy groups, and civil society organisations.

Post-grant opposition (Section 25(2)): Any person can file a post-grant opposition within 12 months of the patent's grant date. Grounds are similar to pre-grant opposition. Post-grant oppositions are decided by an opposition board and the Controller.

Revocation (Section 64): The Intellectual Property Appellate Board (IPAB) — reconstituted and merged into the High Courts following 2021 legislative reform — handles revocation petitions, which can be filed at any time during the patent's life.

For pharmaceutical inventors: Assume that any significant pharmaceutical patent will face pre-grant or post-grant opposition. File early to maximise examination time before opposition. Prepare strong technical arguments — including clinical data — in advance. Engage experienced Indian pharmaceutical patent counsel from the outset.

The Filing Process

Step 1: Patent Search and Freedom to Operate

Conduct a thorough prior art search covering:

• Indian patent applications and grants (InPASS — ipindiaonline.gov.in)
• Standard international databases (Google Patents, Espacenet, WIPO PATENTSCOPE)
• Indian scientific and technical literature — India's substantial academic and pharmaceutical research output is prior art

For pharmaceutical inventions, specifically search Indian pharmaceutical patent filings, which constitute a major portion of the Indian patent database.

Step 2: Prepare the Application

Specification requirements: The Indian Patents Act requires the complete specification to:

• Describe the invention fully and particularly
• Disclose the best method of performing the invention known to the applicant at filing
• Set out distinctly the scope of the invention claimed (in the claims)

Claims: Indian claims must be clear, fairly based on the specification, and accompanied by an abstract. There is no explicit limit on the number of claims, but claims fees increase for claims beyond 10 (approximately INR 800 per additional claim for a natural person).

Working examples: For pharmaceutical and chemical inventions, working examples with experimental data are strongly advisable. Indian examiners and opposition boards scrutinise whether claims are adequately supported by working examples — particularly for pharmaceutical inventions subject to Section 3(d) challenges.

Step 3: File the Application

Who can file: Foreign applicants must appoint an Indian patent agent registered with the IPO. Direct prosecution by foreign parties is not permitted.

Filing options:

• Ordinary application (national filing, claiming no priority)
• Convention application (claiming Paris Convention priority within 12 months of first filing in a convention country)
• PCT national phase application (within 31 months of the international priority date — India offers the 31-month deadline, one month longer than the standard PCT rule)
• National phase applications must be accompanied by a full Indian translation (the specification must be in English or Hindi)

Provisional specification: India's provisional specification system allows filing a preliminary description of the invention (not the full specification) to establish a priority date, with 12 months to file the complete specification. This is functionally similar to the US provisional application, though structurally different. It establishes an Indian priority date at low cost while the complete application is prepared.

Step 4: Request for Examination

Substantive examination must be requested separately within 48 months of the earliest priority date (extended from 36 months in a 2019 amendment). If no examination request is filed within this period, the application is treated as withdrawn.

Expedited examination: India offers expedited examination for:

• Startups (defined under DPIIT guidelines)
• Small entities and natural persons
• Government undertakings
• Applicants whose invention is in relation to a notified area under specific programmes
• Applications where PCT examination has already occurred

Under expedited examination, first examination typically issues within 6–12 months — substantially faster than standard examination.

Examination request fee: INR 4,000–8,000 (approx. USD $48–$96) for natural persons and small entities; INR 20,000–40,000 for others. Among the lowest examination fees of any major jurisdiction.

Step 5: Examination and First Examination Report (FER)

The IPO's first Office Action is called the First Examination Report (FER). It follows a format similar to other major offices, citing prior art and applicable statutory provisions.

Response period: 12 months from the FER date. This is the longest standard response period of any major patent office — a genuine advantage for inventors who need time to gather experimental data, commission expert opinions, or conduct further analysis.

Common rejection grounds in India:

Section 3(d) rejections (pharmaceutical inventions): As discussed — requiring demonstration of significantly enhanced therapeutic efficacy.

Lack of inventive step (Section 2(1)(ja)): Must involve a feature that makes the invention not obvious to a person skilled in the art. Indian examination applies the "could/would" test: whether a skilled person would have been motivated (not merely could have been motivated) to combine references to arrive at the claimed invention.

Sufficiency of disclosure (Section 10(4)): The specification must fully and particularly describe the invention and the best method of performing it. Indian examiners pay particular attention to whether working examples support the breadth of the claims.

Not an invention under Section 2(1)(j): Covers Section 3 exclusions. Examiners routinely apply Section 3(k) to software claims and Section 3(d) to pharmaceutical derivative claims.

A Worked Scenario: Pharmaceutical Patent in India

A European biotechnology company filed an Indian patent application for a new crystalline polymorph of an established antidiabetic compound, along with a method of manufacture.

FER (issued 4 years after PCT national phase entry):

Rejection 1 (Section 3(d)): The examiner rejected the polymorph claims on the grounds that a crystalline polymorph is a "new form of a known substance" and no evidence of significantly enhanced therapeutic efficacy had been submitted.

Rejection 2 (lack of inventive step): The examiner cited two prior art references — a European patent and an Indian journal publication — arguing that the claimed manufacturing method was obvious to a skilled chemist.

Response strategy:

Rejection 1: The applicant submitted clinical data demonstrating that the new polymorph achieved 35% greater oral bioavailability, which translated to reduced dosage requirements and improved glycaemic control in comparative clinical studies. The response argued that improved bioavailability that leads to documented enhanced clinical efficacy (not merely improved physicochemical properties) satisfies Section 3(d). This argument — supported by clinical evidence — distinguished the case from the Novartis scenario, where the efficacy improvement relied on bioavailability alone.

Rejection 2: The applicant pointed to a specific distinction in the manufacturing process: a crystallisation step conducted at a specific temperature range (4°C–8°C with a specific cooling rate) that was not described in either prior art reference and that produced the specific polymorph with its enhanced bioavailability. An expert declaration from a pharmaceutical chemist explained that the specific temperature and cooling rate parameters were not predictable from the prior art and required inventive insight to discover.

Result: After one further exchange and a hearing before the Controller, the polymorph claims were allowed subject to amendment to specify the clinical efficacy data in the claim preamble. The manufacturing method claims were allowed without further amendment. The patent granted 6 years after PCT national phase entry — slower than European or US counterparts, but producing a commercially valuable Indian patent.

Lessons: Section 3(d) is navigable with genuine clinical efficacy data. Distinguish bioavailability improvements (insufficient on their own) from documented clinical benefit (sufficient). Expert declarations are effective in Indian examination.

Enforcement in India

The High Courts

Patent infringement actions in India are heard by the District Courts or the High Courts. The Delhi High Court's IP Division has become the primary venue for significant patent cases — it handles a large proportion of Indian pharmaceutical patent litigation and has developed substantial expertise.

Timeline: First-instance proceedings in significant cases take 3–7 years, longer than most other major jurisdictions. Interim injunctions — which can be obtained relatively quickly (within months) — are strategically important in Indian patent litigation. An interim injunction against a generic manufacturer effectively prevents market entry pending the full trial.

Interim injunctions: Indian courts apply a three-part test: prima facie case, balance of convenience, and irreparable harm. For pharmaceutical patent holders asserting against generic manufacturers, establishing a prima facie case requires demonstrating a plausible infringement argument and patent validity — the pre-grant opposition history and FER correspondence are closely scrutinised by courts assessing validity.

Damages

Indian patent damages are calculated on principles similar to other common law jurisdictions — actual damages, including lost profits or reasonable royalty. Damages awards have historically been modest relative to the scale of some Indian infringement cases, though courts have demonstrated increasing willingness to award meaningful damages in appropriate cases.

IPAB Reform

The Intellectual Property Appellate Board (IPAB) was abolished in 2021, with its functions transferred to the respective High Courts. Patent revocation proceedings (previously before IPAB) are now filed directly at the High Courts. This reform has been welcomed for bringing IP appeals into the mainstream judicial system, though the transition has created some procedural uncertainty that is working its way through the system.

India-Specific Strategic Considerations

Use the provisional specification to buy time. India's provisional specification system allows filing a rough disclosure to establish an Indian priority date at very low cost, with 12 months to complete the application. This is particularly useful for inventions still being developed where the complete specification is not ready.

File early to front-run opposition. Pre-grant oppositions cannot be filed until the application is published (18 months after priority). An application filed early — with a provisional specification, then a complete specification — maximises the examination time before an opposition can be filed and gives more time to build the evidentiary record.

Prepare clinical or experimental data in advance for pharmaceutical inventions. Section 3(d) challenges require evidence of enhanced therapeutic efficacy. This data should be prepared before filing, not gathered in response to an FER. Indian examiners can request data during examination; having it ready accelerates prosecution significantly.

India as a licensing market for non-pharmaceutical inventions. Outside the pharmaceutical sector, India's patent landscape is less contentious. Technology, manufacturing, agricultural, and clean energy patents in India provide genuine commercial protection. India's burgeoning startup ecosystem, its position as a global technology services hub, and its national programmes (Make in India, Atmanirbhar Bharat) are creating demand for licensed technology in manufacturing, energy, and infrastructure. Indian patent protection supports licensing negotiations with Indian manufacturers and government procurement entities.

Cost Summary

Indian patent prosecution is among the most cost-effective of any major jurisdiction in terms of government fees. Attorney fees are also competitive relative to Western markets.

Sources

1. Indian Patent Office (Controller General of Patents, Designs and Trade Marks) — Official patent office; filing procedures, fee schedules, and examination guidelines
2. Indian Patents Act 1970 (as amended) — Full text of the statute including Sections 3(d), 3(k), and opposition provisions
3. InPASS — Indian Patent Search — Official online patent search and e-filing portal
4. WIPO — India Country Profile — Treaty memberships and IP office information

Information current as of April 2026. Patent fees, timelines, and office procedures change — verify with the national patent office before filing.